Research progress of bile acid metabolism in complications of liver cirrhosis

Abstract

Abstract: Bile acids are synthesized from cholesterol in hepatocytes and play an important role in the absorption, transport and distribution of fat and fat soluble vitamins. They also act as important signal molecules to regulate metabolism and inflammatory response. The accumulation of bile acids in the body and the activation of bile acid related receptors can aggravate or alleviate the complications of liver cirrhosis such as hepatic encephalopathy, portal hypertension and peritonitis.

Key words: bile acid, hepatic encephalopathy, portal hypertension, peritonitis

CLC Number:

R512.6

ZHANG Xue-mei, LI Jun-feng, MAO Xiao-rong. Research progress of bile acid metabolism in complications of liver cirrhosis[J]. Basic & Clinical Medicine, 2021, 41(1): 103-107.

References

[1] Yang YM, Roh YS,Seki E. MafG a novel target of FXR that regulates bile acid homeostasis[J]. Gastroenterology,2015, 149: 1981-1983.
[2] Xu Y, Li F, Zalzala M, et al. Farnesoid X receptor activation increases reverse cholesterol transport by modulat-ing bile acid composition and cholesterol absorption in mice[J]. Hepatology, 2016, 64: 1072-1085.
[3] Pathak P, Xie C, Nichols RG, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabo-lism[J]. Hepatology, 2018, 68: 1574-1588.
[4] Schwabl P, Hambruch E, Seeland BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction[J]. J Hepatol, 2017, 66: 724-733.
[5] Shetty S,Boyer JL. Bile acid metabolism and T cell responses in cholangiopathy: not one-way traffic[J]. J Hepatol,2019, 71: 657-659.
[6] Guo C, Xie S, Chi Z, et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome[J]. Immunity, 2016, 45: 802-816.
[7] Horvatits T, Drolz A, Roedl K, et al. Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis[J]. Liver Int,2017, 37: 224-231.
[8] Weiss N, Barbier Saint Hilaire P, Colsch B, et al. Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy[J]. J Hepatol, 2016, 65: 1120-1130.
[9] Acharya C,Bajaj JS. Gut microbiota and complications of liver disease[J]. Gastroenterol Clin North Am,2017, 46: 155-169.
[10] Ahluwalia V, Betrapally NS, Hylemon PB, et al. Impaired gut-liver-brain axis in patients with cirrhosis[J]. Sci Rep, 2016, 6: 26800.doi:10.1038/srep26800.
[11] Bajaj JS,Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis[J]. J Hepatol, 2020. doi:10.1016/j.jhep.2020.01.017.
[12] Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrho-sis and its complications[J]. J Hepatol, 2014, 60: 940-947.
[13] Baffy G. Potential mechanisms linking gut microbiota and portal hypertension[J]. Liver Int, 2019, 39: 598-609.doi:10.1111/liv.13986.
[14] Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360.doi:10.1126/science.aan5931.
[15] Xie G, Wang X, Jiang R, et al. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure[J]. EBioMedicine, 2018, 37: 294-306.
[16] Jia W, Rajani C, Kaddurah-Daouk R, et al. Expert insights: the potential role of the gut microbiome-bile acid-brain axis in the development and progression of Alzheimer's disease and hepatic encephalopathy[J]. Med Res Rev,2019. doi:10.1002/med.21653.
[17] McMillin M, Frampton G, Grant S, et al. Bile acid-mediated sphingosine-1-phosphate receptor 2 signaling pro-motes neuroinflammation during hepatic encephalopathy in mice[J]. Front Cell Neurosci, 2017, 11: 191.doi:10.3389/fncel.2017.00191.
[18] Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial[J]. The Lancet, 2019, 393: 1597-1608.
[19] Fiorucci S,Distrutti E. Targeting the transsulfuration-H₂S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension[J]. Pharmacol Res,2016, 111: 749-756.
[20] Mookerjee RP, Mehta G, Balasubramaniyan V, et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension[J]. J Hepatol,2015, 62: 325-331.
[21] Xu W, Lu C, Zhang F, et al. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction[J]. FEBS J, 2017, 284: 114-133.
[22] Fiorucci S, Zampella A, Cirino G, et al. Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators[J]. Am J Physiol Heart Circ Physiol, 2017, 312: H21-H32.
[23] Li YT, Yu CB, Huang JR, et al. Pathogen profile and drug resistance analysis of spontaneous peritonitis in cirrhotic patients[J]. World J Gastroenterol, 2015, 21: 10409-10417.
[24] Sorribas M, Jakob MO, Yilmaz B, et al. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis[J]. J Hepatol, 2019, 71: 1126-1140.
[25] Lachar J,Bajaj JS. Changes in the microbiome in cirrhosis and relationship to complications: hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis[J]. Semin Liver Dis, 2016, 36: 327-330.
[26] Chavez-Talavera O, Tailleux A, Lefebvre P, et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152: 1679-1694.